BPC
CRL icon

Bryce Point Capital’s Charles River Laboratories CRL Stock Holding History

Bryce Point Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,898
Closed -$535K – 244
2024
Q4 		$535K Buy
+2,898
New +$558K 0.16% 219

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bryce Point Capital's CRL Position: Q1 2025 in Review

Bryce Point Capital sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 2,898 shares — an estimated $535K sold.

Bryce Point Capital first reported a position in CRL in Q4 2024 and held it in 1 quarter. The position peaked at $535K in Q4 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Bryce Point Capital reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 2,898 Charles River Laboratories shares in Q1 2025, an estimated $535K.
  • Bryce Point Capital first reported a position in Charles River Laboratories in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Charles River Laboratories position peaked at $535K in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.